New Strategic Vision for Biotechnology Innovation Organization
Shifting to a proactive voice for science that will drive a “bio revolution” WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) today
North America
Novartis presentation includes new data on recently FDA-approved Kesimpta
Novartis will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.
More from North America
Europe
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1
